Article thumbnail

Transarterial embolisation of hepatocellular carcinoma with doxorubicin-eluting beads: single centre early experience

By O Nawawi, MN Hazman, BJJ Abdullah, A Vijayananthan, J Manikam, S Mahadeva and KL Goh
Topics: Original Article
Publisher: Department of Biomedical Imaging, Faculty of Medicine, University of Malaya, Malaysia
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2005). 11-15, abstract P485]. Varela
  2. (1995). A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire.
  3. (2007). A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol
  4. (2007). Acute pancreatitis after embolization of liver tumors: frequency and associated risk factors. Pancreatology
  5. (2005). Anatomic and technical skill factor of gastroduodenal complication in post-transarterial embolization for hepatocellular carcinoma: a retrospective study of 280 cases.
  6. (2002). Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet
  7. (2008). Biomed Imaging Interv J 2010; 6(1):e7 8 This page number is not for citation purposes chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Intervent Radiol
  8. (2007). Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics.
  9. (2007). Chemoembolization of hepatocellular carcinoma with drug eluting beads.
  10. (2005). Clinical experience with drug eluting bead (DC Bead) for chemoembolisation of unresectable hepatocellular carcinoma. [Data presentation at CIRSE
  11. (2001). Clinical management of hepatocellular carcinoma.
  12. (2006). DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol
  13. (2008). Drug-loaded microspheres for the treatment of liver cancer: review of current results. Cardiovasc Intervent Radiol
  14. (1999). Epidemiology of primary liver cancer. Semin Liver Dis
  15. (1981). Hepatic artery infusion chemotherapy: gastroduodenal complications.
  16. (2003). Hepatocellular carcinoma. Lancet
  17. (2003). Histopathological landmarks of hepatocellular carcinoma in Malaysians.
  18. (2002). International Agency for Cancer Research. GLOBOCAN
  19. (2001). Liver abscess after transcatheter oily chemoembolization for hepatic tumors: incidence, predisposing factors, and clinical outcome. J Vasc Interv Radiol
  20. (2007). Liver resection for HCC: analysis of causes and risk factors linked to postoperative complications. Hepatogastroenterology
  21. (2007). Liver resection or combined chemoembolization and radiofrequency ablation improve survival in patients with hepatocellular carcinoma. Digestion
  22. (2006). New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res
  23. (2002). Orlando A et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology
  24. (1993). Pancreatic tissue damage by transcatheter arterial embolization for hepatoma. Dig Dis Sci
  25. (1999). Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis
  26. (1997). Prospective randomized trial of chemoembolization versus intra-arterial injection of 131Ilabeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology
  27. (2007). Radioembolization with 90Y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol
  28. (2006). Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). Eur Radiol
  29. (2002). Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology
  30. (1998). Ruptured hepatocellular carcinoma as a complication of transarterial oily chemoembolization.
  31. (2007). Ruptured hepatocellular carcinoma following chemoembolization: a western experience. Hepatobiliary Pancreat Dis Int
  32. (2002). Sauvanet A et al. [Acute clinical pancreatitis following selective transcatheter arterial chemoembolization of hepatocellular carcinoma]. Ann Chir
  33. (2006). Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies.
  34. (2006). Study of severe and rare complications of transarterial chemoembolization (TACE) for liver cancer.
  35. (2003). Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology
  36. (2001). Targeted transarterial oily chemoembolization for small foci of hepatocellular carcinoma using a unified helical CT and angiography system: analysis of factors affecting local recurrence and survival rates.
  37. (2006). Technology insight: Image-guided therapies for hepatocellular carcinoma--intra-arterial and ablative techniques. Nat Clin Pract Oncol
  38. (2001). The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: implications for diagnostic radiologists.
  39. (2007). Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol
  40. (1979). Transcatheter occlusion of the gastroduodenal artery. Radiology
  41. (2004). Treatment of Asian patients with hepatocellular carcinoma (HCC) using doxorubicin eluting beads embolization
  42. (1998). Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC.